Pfizer-BioNTech has been granted FDA (Food and Drug Administration) authorization for its booster shot for people aged 65 and older, as well as individuals at high risk for severe disease and those working in patient-facing healthcare, six months are their second dose. According to the (Centers for Disease Control and Prevention), Americans over the age of 65 make up about 17% of the U.S. population, and have accounted for more than 77% of all deaths from COVID-19. Before FDA’s Vaccines and Related Biological Products Advisory Committee universally voted in favor of this booster shot for older people, Pfizer presented data from the U.S. and Israel evaluating the efficacy of the COVID-19 vaccine drops over time. The data further indicated that reduced immunity is caused by waning immunity and the Delta variant.
Learn more here.